Integral Diagnostics Crescita futura
Criteri Future verificati 4/6
Integral Diagnostics prevede che gli utili e i ricavi cresceranno rispettivamente di 27.6% e 6.4% all'anno. Si prevede che l'EPS crescerà di 28.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 9.8% in 3 anni.
Informazioni chiave
27.6%
Tasso di crescita degli utili
28.15%
Tasso di crescita dell'EPS
| Healthcare crescita degli utili | 15.8% |
| Tasso di crescita dei ricavi | 6.4% |
| Rendimento futuro del capitale proprio | 9.76% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 30 Jun 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance
Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.
IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.IDX: Merger Synergies And New Sites Will Support Future Upside
Analysts have made a small upward adjustment to their price target for Integral Diagnostics, which now sits slightly higher in A$ terms. This reflects modest tweaks to their fair value, discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.IDX: Inorganic Expansion And Merger Synergies Will Drive Future Upside
Analysts have trimmed their price target for Integral Diagnostics from around A$3.36 to about A$3.12, reflecting updated assumptions for slightly lower revenue growth, modestly softer profit margins and a reduced future P/E multiple. What's in the News Management is actively assessing M&A options and continuing to look at inorganic growth, alongside opening 3 new greenfield sites in the last quarter of the financial year in Eastwood Private Hospital (South Australia), Wangaratta (Victoria) and Maroochydore (Queensland), plus a relocation to a new facility in Launceston (Key Developments).Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Despite a sharp reduction in projected revenue growth, the consensus future P/E multiple for Integral Diagnostics has contracted significantly, supporting a higher analyst price target of A$3.34. Valuation Changes Summary of Valuation Changes for Integral Diagnostics The Consensus Analyst Price Target has risen from A$3.12 to A$3.34.
Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch
Integral Diagnostics Limited ( ASX:IDX ) shareholders that were waiting for something to happen have been dealt a blow...Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Key Insights Integral Diagnostics will host its Annual General Meeting on 28th of November Total pay for CEO Ian Kadish...Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced that on 4th of April, it will be paying a dividend ofA$0.025...These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
While Integral Diagnostics Limited ( ASX:IDX ) might not be the most widely known stock at the moment, it saw...Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced it will be reducing its dividend payable on the 4th of April to...Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Does the February share price for Integral Diagnostics Limited ( ASX:IDX ) reflect what it's really worth? Today, we...Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
The performance at Integral Diagnostics Limited ( ASX:IDX ) has been quite strong recently and CEO Ian Kadish has...Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 6/30/2029 | 977 | 72 | 76 | 159 | 3 |
| 6/30/2028 | 904 | 62 | 70 | 138 | 11 |
| 6/30/2027 | 853 | 53 | 68 | 131 | 12 |
| 6/30/2026 | 803 | 30 | 48 | 104 | 12 |
| 12/31/2025 | 768 | 14 | 27 | 85 | N/A |
| 9/30/2025 | 698 | 9 | 20 | 79 | N/A |
| 6/30/2025 | 627 | 5 | 14 | 74 | N/A |
| 3/31/2025 | 559 | 5 | 24 | 73 | N/A |
| 12/31/2024 | 491 | 6 | 34 | 73 | N/A |
| 9/30/2024 | 481 | -28 | 38 | 70 | N/A |
| 6/30/2024 | 470 | -61 | 42 | 66 | N/A |
| 3/31/2024 | 463 | -59 | 29 | 62 | N/A |
| 12/31/2023 | 456 | -58 | 16 | 58 | N/A |
| 9/30/2023 | 449 | -16 | 20 | 63 | N/A |
| 6/30/2023 | 441 | 25 | 23 | 67 | N/A |
| 3/31/2023 | 418 | 23 | 20 | 56 | N/A |
| 12/31/2022 | 395 | 21 | 17 | 45 | N/A |
| 9/30/2022 | 378 | 18 | 13 | 41 | N/A |
| 6/30/2022 | 361 | 15 | 9 | 37 | N/A |
| 3/31/2022 | 361 | 18 | 14 | 41 | N/A |
| 12/31/2021 | 360 | 22 | 18 | 44 | N/A |
| 9/30/2021 | 356 | 26 | 34 | 57 | N/A |
| 6/30/2021 | 351 | 31 | 49 | 70 | N/A |
| 3/31/2021 | 333 | 32 | 54 | 73 | N/A |
| 12/31/2020 | 315 | 32 | 59 | 76 | N/A |
| 9/30/2020 | 295 | 28 | 44 | 65 | N/A |
| 6/30/2020 | 276 | 23 | 28 | 54 | N/A |
| 3/31/2020 | 263 | 22 | 19 | 47 | N/A |
| 12/31/2019 | 250 | 21 | 9 | 39 | N/A |
| 9/30/2019 | 241 | 21 | N/A | 37 | N/A |
| 6/30/2019 | 232 | 21 | N/A | 34 | N/A |
| 3/31/2019 | 222 | 19 | N/A | 30 | N/A |
| 12/31/2018 | 211 | 17 | N/A | 26 | N/A |
| 9/30/2018 | 200 | 16 | N/A | 26 | N/A |
| 6/30/2018 | 189 | 15 | N/A | 27 | N/A |
| 3/31/2018 | 187 | 15 | N/A | 27 | N/A |
| 12/31/2017 | 185 | 15 | N/A | 27 | N/A |
| 9/30/2017 | 182 | 15 | N/A | 25 | N/A |
| 6/30/2017 | 180 | 15 | N/A | 23 | N/A |
| 3/31/2017 | 177 | 16 | N/A | 26 | N/A |
| 12/31/2016 | 175 | 16 | N/A | 30 | N/A |
| 9/30/2016 | 171 | 14 | N/A | 27 | N/A |
| 6/30/2016 | 168 | 11 | N/A | 24 | N/A |
| 3/31/2016 | 165 | 11 | N/A | 22 | N/A |
| 12/31/2015 | 162 | 11 | N/A | 20 | N/A |
| 9/30/2015 | 157 | 8 | N/A | 18 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di IDX ( 27.6% all'anno) è superiore al tasso di risparmio ( 3.6% ).
Guadagni vs Mercato: Si prevede che gli utili di IDX ( 27.6% all'anno) cresceranno più rapidamente del mercato Australian ( 11.5% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di IDX cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di IDX ( 6.4% all'anno) crescerà più rapidamente del mercato Australian ( 6% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di IDX ( 6.4% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di IDX sarà basso tra 3 anni ( 9.8 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/02 01:13 |
| Prezzo dell'azione a fine giornata | 2026/07/02 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/06/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Integral Diagnostics Limited è coperta da 22 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Thomas Yeo | Barrenjoey Markets Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Benjamin Brayshaw | Barrenjoey Markets Pty Limited |